Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1993-04-22
1997-02-04
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514327, A61K 3170, A61K 31445
Patent
active
055997945
ABSTRACT:
The invention consists of a combination of a substance that increases the intragastric pH and an acid degradable antibacterial compound. By this combined product regimen it will be possible to obtain maximal local antibacterial effect of acid degradable antibiotics as well as enhanced bioavailability of the active antibiotic, thus resulting in higher amounts of the active compound in the gastric mucosa due to secretion of weak bases. Both pharmacological effects contribute to drastically increased antimicrobial capacity of acid degradable antibiotics to be used against local infections in the gastrointestinal tract causing gastritis and/or peptic ulcer. The invention also selects to the use of said combination and a process for the preparation thereof.
REFERENCES:
patent: 5013743 (1991-05-01), Iwahi et al.
patent: 5093342 (1992-03-01), Tomoi et al.
Logan et al, The Lancet, vol. 340, Jul. 25, 1992 Abstract Drug Thev Boll 1991, 29; 26 reference (see foot note #9).
Chemical Abstracts 104:203737 j (1986).
Chemical Abstracts 106:182648l (1987).
P. Unge, et al. "Does Omeprazole, 40 mg o.m. improve antimicrobial therapy directed towards gastric Campylobacter-pylori in patients . . . " Scandinavian Journal of Gastroenterology 1989, 24 (Suppl. 166) p. 184 (ABSTRACT).
P. Unge, et al. "Does Omeprazole improve antimicrobial therapy directed towards gastric Campylobacter-pylori in patients with antral gastritis" Scandinavian Journal of Gastroenterology 1989, 24 (Suppl. 167) p. 49-54 (ARTICLE).
"Which regimen for H pylori eradication?" SCRIP No. 1861 Oct. 5, 1983, p. 23.
S. Rune, "Helicobacter pylori, Peptic Ulcer Disease and Inhibition of Gastric Acid Secretion" Digestion 1992; 51 (Suppl. 1): 11-16.
McDermott, et al., Science, The Absorption of Orally Administered Penicillin, Mar. 22, 1946, pp. 359-361.
McNulty, et al., Eur. J. Clin. Microbiol. Infect. Dis., Susceptibility of Clinical Isolates, Aug., 1988, pp. 566-569.
The Lancet, Clarithromycin and Omeprazole, vol. 340, Jul. 25, 1992.
Goodwin, Worsley, Peptic Ulcer Disease, 1992, Current Science, 8:122-127.
Loo, Sherman, Matlow; Helicobacter pylori Infection, Anti-microbial Agents & Chemotherapy, May, 1992, pp. 1133-1135.
Eek Arne T.
Sj ostrand Sven Erik
Aktiebolaget Astra
Goldberg Jerome D.
LandOfFree
Synergistic combination of a substance with gastric acid secreti does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synergistic combination of a substance with gastric acid secreti, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synergistic combination of a substance with gastric acid secreti will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-678659